DS42450411
DS42450411 is an orally active hepcidin production inhibitor with an IC50 of 32 nM. DS42450411 in an acute inflammatory mouse model induced by IL-6, DS42450411 significantly reduces serum hepcidin levels. DS42450411 can be used for studying iron homeostasis.
For research use only. We do not sell to patients.
- CAS No.: 2247168-13-2
- Formula: C22H28N4
- Molecular Weight:348.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
0.032 μM
Compound: 34; DS42450411
|
Inhibition of BMP6-stimulated hepcidin production in human HepG2 cells
Inhibition of BMP6-stimulated hepcidin production in human HepG2 cells
|
[PMID: 30217414] |
Chemical Information
-
CAS No. 2247168-13-2
-
Molecular Weight 348.48
-
Formula C22H28N4
-
SMILES
NC1=C2C(C)(C)CC3=CC(C([C@H]4CC[C@H](N)CC4)=C)=CC=C3C2=NC=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)